Zacks Research Has Negative Forecast for BIO Q4 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities researchers at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for Bio-Rad Laboratories in a report issued on Wednesday, December 18th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $3.21 for the quarter, down from their previous forecast of $3.28. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.29 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2026 earnings at $3.16 EPS.

Other research analysts have also recently issued research reports about the stock. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. Royal Bank of Canada lifted their price objective on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a research report on Monday, December 9th. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Citigroup boosted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.20.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $330.53 on Monday. The stock has a 50-day simple moving average of $340.22 and a two-hundred day simple moving average of $323.44. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories has a 52-week low of $262.12 and a 52-week high of $387.99. The firm has a market capitalization of $9.25 billion, a PE ratio of -12.09 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. The company had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. Bio-Rad Laboratories’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.33 earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. UMB Bank n.a. raised its position in shares of Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories in the third quarter worth about $32,000. Headlands Technologies LLC purchased a new stake in shares of Bio-Rad Laboratories during the second quarter valued at about $51,000. Point72 Hong Kong Ltd bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $55,000. Finally, Quarry LP purchased a new position in shares of Bio-Rad Laboratories in the 2nd quarter worth approximately $59,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.